Strengthening its commitment to oncology, Pfizer has entered into a collaboration with Arvinas to develop and commercialise an investigational oral proteolysis targeting chimera (PROTAC) oestrogen receptor protein degrader, ARV-471, for the treatment of breast cancer. The deal is worth a total of US$2.4 B with Arvinas receiving an upfront payment of US$650 M and an investment of US$350 M equivalent to a 7% stake in the company from Pfizer. With the deal Pfizer gains an access to the first ever PROTAC for breast cancer, ARV-471.